No Data
No Data
Stocks to Watch: Levi Strauss, Casi Pharmaceuticals, Recursion Pharmaceuticals, Aterian
By Sabela Ojea Levi Strauss reported lower-than-expected revenue in its fiscal second quarter and left its outlook for the year unchanged. Shares of the jeans maker fall 12%, to $20.28, in after-hour
Aterian Names Rodriguez Chief Executive After Co-CEO Risico Resigns
By Sabela Ojea Aterian named Arturo Rodriguez chief executive following the resignation of Joe Risico as co-CEO. The technology-enabled consumer products company on Wednesday said that, as part of m
Aterian Shares Are Trading Higher After the Company Announced a CEO Change and Increased Its Q2 Revenue Outlook.
Aterian Shares Are Trading Higher After the Company Announced a CEO Change and Increased Its Q2 Revenue Outlook.
Aterian: Cash Balance as of June 30 Expected Between $17M and $18M and Borrowing Under Its Credit Facility Is Expected to Be Approximately $10M >ATER
Aterian: Cash Balance as of June 30 Expected Between $17M and $18M and Borrowing Under Its Credit Facility Is Expected to Be Approximately $10M >ATER
Aterian Sees 2Q Rev $23M-$26M >ATER
Aterian Sees 2Q Rev $23M-$26M >ATER
Aterian: Joe Risico Has Resigned as Co-CEO and From the Bd of Directors, Will Consult the Co Over a Three-Mo Transition Period >ATER
Aterian: Joe Risico Has Resigned as Co-CEO and From the Bd of Directors, Will Consult the Co Over a Three-Mo Transition Period >ATER